AMGN AMGEN INC
What matters nowUpdated 11 h ago
- The latest development is positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease, announced on September 22, 2026. The study met its primary endpoint at week 48, but Amgen gave no effect sizes 1.
- AMGN traded at $416.69 on the pooled 24/7 venue price, down 0.26% from the previous close. The stock fell 5.12% on September 8, the day Amgen reported the DeLLphi-305 result for IMDELLTRA plus Imfinzi 2, and rose 4.46% on September 22, the day of the dazodalibep readout 1.
- Q2 2026 revenue was $10.05 billion, up 10% from a year earlier 3, and full-year 2026 non-GAAP EPS guidance is $22.30 to $23.50 4. Over the twelve months to June 30, 2026, revenue was $38.10 billion (up 9.1%), EPS was $16.10 (up 31.6%), the operating margin was 30.0%, the P/E was 25.9 and EV/EBITDA was 19.0, with net debt of $43.3 billion. Insiders sold 11,349 shares worth $4.51 million over the past 180 days and bought none.
- Product lines diverge: in Q2 2026 Repatha sales rose 37% to $953 million, EVENITY rose 38% to $714 million and IMDELLTRA more than doubled to $288 million, while Prolia fell 32% to $759 million and XGEVA fell 34% to $352 million as biosimilars take share.
- Next, Q3 2026 earnings are expected on November 3, 2026, though the date is not confirmed. The second dazodalibep Phase 3 study, OASIZ 303, is expected to complete in Q4 2026 1. Polymarket odds give an 81.5% chance of no Fed rate change after the October 2026 meeting and 17.5% for a 25 bp increase, and September CPI is due October 14, 2026.
Amgen press release (September 22, 2026) · Sep 22
Amgen press release (September 8, 2026) · Sep 8
SEC EDGAR · Aug 4
Amgen press release (Q2 2026 results) · Aug 4
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Every venue
| Venue | Price | vs pool | 24h vol | Open int. | Funding 8h |
|---|---|---|---|---|---|
| bybit perp AMGNUSDT · just now | 412.91 | −0.03% | $28.7K | $63.9K | 0.0000% |
| bitget perp AMGNUSDT · just now | 413.96 | +0.22% | $17.8K | $15.5K | 0.0000% |
Pooled price = volume-weighted median of venues within 2% of each other. Venue markets for stocks, indices and gold are 24/7 perpetual contracts; they track but are not the official exchange price.
Open interest, 120 days
US$ millions, all venues
Funding, 120 days
Annualised %, OI-weighted. Positive: longs pay shorts.
NewsAll news →
Dazodalibep meets primary endpoint in first Phase 3 study in systemic Sjogren's disease
Amgen reported positive topline results on September 22, 2026 from OASIZ 301, a Phase 3 study of dazodalibep in moderate-to-severe systemic Sjogren's disease.
FDA cuts IMDELLTRA first-dose monitoring window to 6 to 8 hours from 22 to 24 hours
The FDA approved a label update on September 14, 2026 that shortens the observation period after the first two IMDELLTRA infusions to 6 to 8 hours, down from 22 to 24 hours.
Amgen to present at Wells Fargo Healthcare Conference on September 10
Amgen said it would present at the Wells Fargo Healthcare Conference at 11:00 a.m.
IMDELLTRA plus Imfinzi improves overall survival in first-line small cell lung cancer
Amgen said on September 8, 2026 that the Phase 3 DeLLphi-305 trial met its primary endpoint at a pre-specified interim analysis.
Thomas Dittrich takes over as Amgen CFO from Peter Griffith
Thomas Dittrich became Amgen's executive vice president and chief financial officer on September 1, 2026, as scheduled in the company's May 2026 announcement.
Repatha linked to 20% lower all-cause mortality in VESALIUS-CV analysis at ESC
Amgen presented a pre-specified secondary analysis of the VESALIUS-CV trial at ESC Congress 2026 on August 31, 2026, showing a 20% reduction in all-cause mortality with Repatha.
AMUNDSEN: immediate evolocumab after heart attack lifts LDL goal rates, misses one-year outcome
The AMUNDSEN study, presented at ESC Congress 2026 in Munich, tested immediate evolocumab before PCI in 2,161 patients with acute heart attack.
TEZSPIRE meets both co-primary endpoints in Phase 3 eosinophilic esophagitis trial
Amgen and AstraZeneca reported positive topline results from the Phase 3 CROSSING trial of TEZSPIRE in eosinophilic esophagitis on August 27, 2026.
Amgen reports fiscal Q2 2026 results: revenue $10.05B, up 10% from a year earlier
Amgen filed a Form 8-K with the SEC on Aug 4, 2026, 4:03 PM ET, reporting an event dated Aug 4, 2026.
Amgen's 2026 outlook: $38.2B to $39.4B revenue and $22.30 to $23.50 non-GAAP EPS
Alongside its second-quarter results, Amgen set full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues, non-GAAP diluted EPS of $22.30 to $23.50, and GAAP diluted EPS of $15.80 to $17.08.
Amgen declares $2.52 per share third-quarter 2026 dividend
Amgen's board approved a dividend of $2.52 per share for the third quarter of 2026, announced July 30, 2026.
EMA committee backs broader Repatha use before a first heart attack or stroke
The European Medicines Agency's CHMP adopted a positive opinion on July 29, 2026 for Repatha in adults with established or high-risk atherosclerotic cardiovascular disease, to reduce cardiovascular risk by lowering LDL cholesterol.
Amgen asks FDA for a hearing to contest proposed withdrawal of Tavneos
Amgen said it submitted data and analyses to the FDA on July 23, 2026, requesting a hearing on the agency's proposal to withdraw approval of TAVNEOS (avacopan).
Federal judge blocks Colorado's price cap on Amgen's Enbrel
A federal judge in Denver granted Amgen a preliminary injunction on July 1, 2026, blocking Colorado's Prescription Drug Affordability Review Board from capping the price of Enbrel while Amgen's lawsuit continues.
Thomas Dittrich rejoins Amgen as executive vice president ahead of CFO handover
Amgen said in May 2026 that Thomas Dittrich would return to the company as an executive vice president on July 1, 2026, before becoming chief financial officer on September 1.